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Progressive renal disease: Role of race and antihypertensive medica-
tions. Hypertension is associated with an accelerated rate of decline in
renal function in patients with chronic renal disease. To identify factors
that might alter the rate of decline in renal function, we reviewed
records of 200 patients from the Nephrology Clinic of the Durham VA
Medical Center who had chronic progressive renal insufficiency. The
average rate of decline in renal function (slope of reciprocal plasma
creatinine versus time) was —0.80 0.62 (SD) mI/mg month in 112 black
patients and —0.84 0.59 in 88 white patients. Multiple regression
analysis indicates that the patient's age, level of diastolic blood pressure
and type of antihypertensive treatment had a significant effect on the
slope of reciprocal creatinine whereas the patient's race and diagnosis
did not. In individual patients, addition of minoxidil or a calcium
channel blocker to other medications significantly lowered blood pres-
sure and slope of reciprocal creatinine. Some antihypertensive medica-
tions lowered blood pressure without significantly affecting the slope.
These data suggest that specific medications may have a favorable
effect on the progression of chronic renal disease by mechanisms in
addition to reduction of blood pressure.
Systemic hypertension appears to be associated with declin-
ing renal function in "normal" people and in patients with
underlying renal insufficiency. In a longitudinal, prospective
study of aging "normal" men, Lindeman, Tobin and Shock [1]
found a negative effect of mean blood pressure on the rate of
decline in creatinine clearance. In patients with renal insuffi-
ciency from diabetic nephropathy, control of hypertension was
associated with a 33% reduction in the rate of decline in
glomerular filtration rate [21. In a retrospective study of a large
group of chronic dialysis patients, the average rate of progres-
sion to end-stage renal disease (ESRD) was faster in patients
with diastolic hypertension than in normotensive patients [3].
Thus, the presence of systemic hypertension appears to have an
adverse effect on renal function over time.
Studies are needed to address the question of whether the
effect of systemic hypertension on progressive renal disease is
due solely to the elevation of blood pressure or due to other
factors that are involved in the pathogenesis of hypertension.
The latter possibility is suggested by observations in black
patients with primary hypertension (hypertension with no other
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known cause of renal disease). These patients appear to prog-
ress to ESRD more frequently than hypertensive white patients
[41 even when blood pressure was "controlled" [5]. The patho-
genesis of essential hypertension in blacks as a group differs
from that in whites and this difference may relate to the
increased frequency of ESRD in black patients [6]. Further
evidence would be finding a specific antihypertensive medica-
tion that blocks the mechanism of renal injury and slows the
progression of renal disease to a greater extent than is observed
from equivalent reductions in diastolic blood pressure with
other medications. Alternatively, if there is no difference be-
tween the effect of antihypertensive medications on the rate of
decline in renal function, then the presence of systemic hyper-
tension would appear to be the main pathogenetic factor.
The objectives of this study were to determine if there were
any differences in the rate of decline in renal function between
black and white patients with progressive renal disease and to
examine the effects of specific types of antihypertensive medi-
cation on the relationship between diastolic blood pressure and
the rate of decline in renal function. We reviewed data from 200
patients (112 black and 88 white) with progressive renal disease
who were followed prior to dialysis at the Durham VA Medical
Center Nephrology Clinic. The relationship between diastolic
blood pressure and rate of decline in renal function as deter-
mined by the slope of reciprocal creatinine versus time was not
different between the races. However, specific antihypertensive
medications, minoxidil and calcium channel blockers, slowed
the rate of decline in renal function more effectively than other
commonly used drugs. These data suggest that specific antihy-
pertensive medications may modify the course of progressive
renal disease by mechanisms in addition to a reduction in
systemic blood pressure.
Methods
The Nephrology Section of the Durham VA Medical Center
has a computerized medical record of all patients seen since
January, 1979 [7]. From this database we performed a retro-
spective and longitudinal study of patients who had progressive
renal insufficiency. The database was screened for patients with
renal insufficiency (plasma creatinine > 1.5 mg/dl) who had at
least four determinations of plasma creatinine and blood pres-
sure over at least six months prior to ESRD treatment and
showed progression of disease as indicated by at least a 20%
decrease in the value of the reciprocal plasma creatinine. From
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the time period between January 1, 1979 and June 1, 1988, we
identified 200 patients who met these criteria; 107 of them had
already reached ESRD. Data from 86 of these patients were
used in our previous report [31. Forthis study we collected data
on race, primary renal diagnosis, plasma creatinine, blood
pressure, weight, and prescribed medications. The average
number of determinations of plasma creatinine per patient was
15.5 1.2 (SE). The medications were prescribed by several
physicians according to their preference. At the time of this
study very few of these patients had a renin profile or treatment
with angiotensin converting enzyme inhibitors. Patients with
moderate renal insufficiency were instructed in a low protein
(0.8 g/kg/day), no added salt diet. Patient compliance with
prescribed medications or diet was not assessed directly.
As in our previous report [31, the change in renal function was
estimated by the slope of the plot of reciprocal plasma creati-
nine versus time [8, 9]. The data of these plots were usually well
described by a single line with the R values for linear regression
analyses being greater than 0.8 in 85% of patients selected by
the above criteria. This determination may not accurately
reflect glomerular filtration rates in these patients [101 but it was
the only quantitative measure of renal function available retro-
spectively on this population. To evaluate the effect of specific
antihypertensive therapy on the rate of change of renal func-
tion, the reciprocal creatinine versus time plots were deter-
mined for each therapeutic plan. When the type of antihyper-
tensive medications was changed, a new slope was determined,
The minimum criteria for calculation of a slope were a duration
of at least six months and at least four determinations of plasma
creatinine. We had data from 280 such intervals with data from
two different treatment plans on 80 patients and data from a
single treatment plan on the remaining 120 patients.
Statistical comparisons and linear regression analyses were
determined with Statview H software (Abacus Concepts,
Berkeley, California, USA). For comparisons of data that were
arranged into multiple groups, we did an analysis of variance to
all groups and applied Fisher's protective least significant
difference test to compare mean values between groups. For
comparison of data between black and white patients we used
the nonparametric Mann-Whitney U test. A paired t-test was
Fig. 1. Effect of diastolic blood pressure on rates of decline in renal
function by race. Bars represent mean ÷ SE of slope from reciprocal
creatinine versus time plots for patients who had diastolic hypertension
(>90 mm Hg) and for patients who were normotensive. Black patients
are represented by hatched bars; white patients are represented by openbars. * indicates values that are significantly different from race-
matched, normotensive values by analysis of variance and a Fisher's
protective least significant difference test (P < 0.05).
used to compare slope data from a single individual at two
periods of time.
Results
Effect of race
Two hundred patients met the selection criteria. These pa-
tients were mostly men (98%); 112 of them were black and 88
were white. Average values of age at last visit, plasma creati-
nine at first and last visit, duration of follow-up, slope of
reciprocal creatinine versus time, systolic and diastolic blood
pressures (mean values from clinic visits during follow-up) are
shown for each race on Table 1. The mean level of diastolic
blood pressure in black patients was significantly higher than
that of white patients (P < 0.01). Other values were not
significantly different. Thus, black patients appeared to be more
hypertensive than white patients, but their rate of change of
reciprocal creatinine was not any faster.
Next we determined if in each race, diastolic hypertension
was associated with a faster rate of decline in reciprocal
creatinine as was previously reported [3]. For this analysis,
patients were sorted by race and the presence or absence of
diastolic hypertension (>90 mm Hg) based on the average value
measured during clinic visits. The average slope for the recip-
rocal creatinine versus time plot was determined for each
subgroup (Fig. 1). Statistical analyses of these data indicate no
difference between the races at each level of blood pressure, but
both hypertensive groups had significantly more negative slopes
than their corresponding normotensive group (P < 0.05). These
data confirm our previous observation [3] and indicate that the
relationship of diastolic hypertension and more rapid decline in
renal function holds for both black and white patients.
Table 1. Characteristics of patients by race
Black patients White patients
Age at last contact 58.9 11.2 56.4 12.3
years
Initial creatinine 3.2 1.8 3.0 1.7
mgldl
Last creatinine 8.4 4.5 7.7 4.2
mg/dl
Duration of follow-up 38.2 25.4 39.7 27.7
months
Slope of 1/Creat vs. time —0.80 0.62 —0.84 0.59
ml/mg month
Systolic blood pressure 155.5 19.2 147.2 16.1
mm Hg
Diastolic blood pressure 91.5 8.7a 87.7 9.1
mm Hg
—0.4
—0.8
—1.2
Values are mean SD for 112 black patients and 88 white patients.
a Indicates values for black patients that are significantly different
from those of white patients by a Mann-Whitney U test (P < 0.05).
No Yes No Yes
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Table 2. Characteristics of population by diagnosis and race
Diastolic BP
mm Hg
Slope of 1/Creat vs. time
mi/mg month
Primary hypertension
Black patients; N = 45 94.2 l.la —0.76 0.09
White patients; N = 22 87.3 1.6 —0.61 0.09
Diabetes mellitus
Black patients; N = 38 90.2 1.7 —0.93 0.10
White patients; N = 19 86.1 2.3 —1.00 0.10
Glomerulonephritis
Black patients; N = 10 89.4 2.5 —0.67 0.10
White patients; N = 21 89.6 1.9 —0.76 0.10
Interstitial nephritis
Black patients; N = 12 86.7 1.6 —0.58 0.20
White patients; N = 11 81.6 2.7 —0.60 0.13
Values are mean SE for N number of patients with each diagnosis.
a Indicates values for black patients that are significantly different
from white patients with the same diagnosis by a Mann-Whitney U test
(P < 0.05)
Table 3. Characteristics of population by age
Diastolic BP Slope of 1/Creat vs. time
mm Hg mi/mg month
Patients <45 years old 92.8 1.3 —0.98 0.10"
N = 34
Patients 45 to 65 years old 89.2 0.9 —0.80 0.06
N = 108
Patients >65 years old 89.2 1.3 —0.76 0.08
N = 58
Values are means SE. N is the number of patients. Statistical
comparisons by Fisher's protective least significant difference test.
a Indicates a value that is significantly different from the diastolic
blood pressure of the other two groupsb Indicates a value that is significantly different from the oldest group
Average values for diastolic blood pressure and slope of
reciprocal creatinine versus time plots as grouped by specific
diagnosis and race are presented on Table 2. Primary hyperten-
sion was present in 40% of black patients and 25% of white
patients. Diabetes mellitus (usually type II) was present in 34%
of black patients and 22% of white patients. The average value
of diastolic blood pressure for black patients with primary
hypertension was significantly higher (P < 0.01) than that
observed in white patients with primary hypertension. Other-
wise, there were no significant differences in the data on this
table.
We used a multiple regression analysis of age, diagnosis,
diastolic blood pressure, and antihypertensive treatment to
determine which factors appeared to have an effect on the slope
of reciprocal creatinine versus time. In this analysis, race (P =
0.70) and diagnosis (P = 0.86) had no significant effect on the
slope, whereas diastolic blood pressure (P 0.012), type of
antihypertensive treatment (P = 0.012) and age (P = 0.04) did.
Effect of age
To analyze the effect of age on the slope of reciprocal
creatinine versus time, we sorted the data into three groups:
patients less than 45 years old at the time of the last creatinine
determination; patients between the age of 45 and 65 years old;
and patients greater than 65 years old. The data for diastolic
blood pressure and slope of reciprocal creatinine versus time
Table 4. Frequency of prescribed antihypertensive medications
Black patients White patients
Diuretic 76% 84%
Beta-blocker 56% 53%
Prazosin 32% 18%
Clonidine 22% 10%
Minoxidil 16% 9%
Ca-channel blocker 8% 12%
Hydralazine 8% 6%
ACE inhibitors 3% 1%
Table 5. Effect of antihypertensive treatment on rate of decline in
renal function in normotensive patients
Treatment N
Diastolic BP
mm Hg
Slope 1/Creat vs. time
mi/mg month
No treatment 26 81.4 1.3 —0.56 009"
Diuretics 28 82.4 1.1 —0.82 0.lla
+ Beta blockers 15 83.8 0.9a —0.58 0.14
+ Prazosin 17 86.3 08a.b —0.84 0.14
+ Two drugs
+ Ca-blockers
27
8
83.5 l.0
78.4 2.6
—0.52 013b
—0.46 0.10"
+ Clonidine 11 84.6 1.7 —0.48 010b
+ Minoxidil 13 85.2 0.9' —0.20 o.ooa,b
Values are means SE. N is the number of patients. Comparisons
between diastolic blood pressure and slope data between groups were
by analysis of variance and a Fisher's protective least significant
difference test.
a Indicates values that are significantly different (P < 0.05) from the
no treatment group
b Indicates values that are significantly different from the diuretic
treatment group
are presented on Table 3. The youngest age group had an
average slope that was significantly different from that of the
oldest (P < 0.05). The mean diastolic blood pressure of the
youngest group was significantly greater than that of either the
middle or older age groups. The patients in the youngest group
were more likely white (53%) and more likely to have a
diagnosis of glomerulonephritis or vasculitis (50%) than patients
in the other age groups. In each age group, the slope of
reciprocal creatinine versus time was the same for black and
white patients.
Effect of specific antihypertensive medications
We determined the slope of the reciprocal creatinine versus
time plot for the time interval that each patient was on a specific
regimen of antihypertensive medications. The frequency of
prescribed antihypertensive medications for black and white
patients are given on Table 4. Because the presence of hyper-
tension has an effect on the slope of reciprocal creatinine versus
time, we separated the data into two groups on the basis of a
normal or hypertensive diastolic blood pressure.
Normotensive patients who were not treated with either a
diuretic or antihypertensive medications had an average slope
of reciprocal creatinine which was significantly less than that of
patients who were treated with diuretics alone, even though the
levels of diastolic blood pressure were equal (Table 5). Addition
of specific antihypertensive drugs such as a combination of two
drugs (beta blocker or clonidine and a vasodilator), a calcium
channel blocker (usually verapamil or nifedipine), clonidine or
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Treatment N
Diastolic BP
mm Hg
Slope l/Creat vs. time
mi/mg month P
Time controls 40 —2,5 1.3 —0.05 0.09 0.78
+ Beta blocker 12 —6.2 1.5 —0.16 0.17 0.18
+ Prazosin 18 —2.6 1.9 +0.12 0.20 0.50
+ Minoxidil 18 —14.2 1.8 +0.53 0.18 0.006
+ Clonidine 12 —4.3 1.8 +0.34 0.24 0.21
+ Ca-blocker 7 —8.8 2.7 +0.53 0.16 0.02
+ Two drugs 11 —7.6 1.6 +0.47 0.30 0.17
minoxidil was associated with significantly slower rates of
change in reciprocal creatinine than treatment with diuretic
alone. Treatment with other antihypertensive medications such
as beta blockers (usually propranolol or atenolol) or prazosin
with a diuretic did not significantly slow the rate of decline in
renal function in this population as compared to patients treated
with only a diuretic. Patients who were treated with minoxidil
had rates of change in reciprocal creatinine that were signifi-
cantly lower than both no treatment and diuretic treatment
groups, even though their average level of diastolic blood
pressure was significantly greater than the control groups.
There were no significant differences between black and white
patients in these responses. These data imply that specific
medications may have a beneficial effect on the rate of decline
in renal function in addition to that observed with control of
diastolic hypertension. In patients who remained hypertensive,
treatment with antihypertensive drugs was associated with no
significant reduction in the rate of change of reciprocal creati-
nine as compared to patients treated with only diuretics (data
not shown). This lack of an effect may be due to an inability to
control diastolic hypertension.
Effect of specific antihypertensive drugs in individual patients
In 80 patients we had sufficient data to determine the slope of
reciprocal creatinine before and after a change in the antihyper-
tensive treatment. Because the reciprocal creatinine versus
time plots are remarkably linear in this population, we can use
the slope of the first treatment interval in a given patient as a
control value to be compared with the slope of the second
treatment interval [3]. In 40 patients who did not have a change
in antihypertensive medication we had enough data to deter-
mine the slope of reciprocal creatinine versus time before and
after an arbitrarily defined mid-point of their follow-up. These
data are time controls and showed no significant change in
either slope or mean value of diastolic blood pressure (Table 6).
In patients who had a new antihypertensive drug prescribed, we
compared the slope of reciprocal creatinine versus time and the
average diastolic blood pressure in time periods following and
preceding the change in medication. These paired differences
are shown on Table 6. Significant improvement in diastolic
blood pressure was observed with all medication changes
except prazosin. Significant slowing of the slope of the recip-
rocal creatinine versus time plot was observed with the addition
of minoxidil or calcium channel blockers. Additions of other
Fig. 2. Effect of specific medications on rate of decline in renal
function in individual patients. Bars represent mean + SE of slope from
reciprocal creatinine versus time plots for individual patients when they
were hypertensive (hatched bars, dBP > 90) and when they were
normotensive (open bars, dBP < 90). The pair of bars on the left are the
data for all patients, including six patients who had no change in
medication. The middle pair of bars are data from patients who received
either minoxidil or a calcium channel blocker to reduce their blood
pressure. The pair of bars on the right are data from patients who
received another drug to lower their blood pressure. * indicates values
that are significantly different by a paired i-test.
antihypertensive medications except beta blockers tended to
improve the slope but were not significant because the benefi-
cial effects were not seen in a majority of patients. Addition of
beta blockers, usually propranolol or atenolol, significantly
reduced diastolic blood pressure but had no effect on the slope
of the reciprocal creatinine versus time plot.
Previously, we have shown that a reduction in diastolic blood
pressure from hypertensive to normotensive values in individ-
ual patients was associated with a less negative slope of the
reciprocal creatinine versus time plot [3]. We repeated this
analysis in the 45 cases where average values of diastolic blood
pressure were lowered from greater than 90 mm Hg to below 90
mm Hg during the time of follow-up. The average slope
improved from —0.76 0.09 mllmg month during the hyper-
tensive period to —0.46 0.09 during the normotensive period
(Fig. 2). Thus as a group, these data confirmed our previous
observation. In subsets of these patients the data were different.
In patients who received minoxidil or calcium channel blockers
and responded with a reduction of their diastolic blood pres-
sures from hypertensive to normotensive values, the slope of
the reciprocal creatinine plot changed from —0.78 0.12 ml/mg
month to —0.24 0.07 (Fig. 2). However, in patients who were
treated with addition of a beta blocker, prazosin, clonidine or a
combination of two of these drugs, the slope of the reciprocal
creatinine was —0.68 0.11 mllmg month when they were
hypertensive and was not different at —0.56 0.13 mI/mg
month after addition of the medication when they were nor-
motensive.
Table 6. Change in diastolic blood pressure and slope of reciprocal
creatinine versus time with addition of specific antihypertensive
treatments in individual patients
Values are mean paired differences SE for data (after minus before
addition of medication) in N number of patients. P values indicate
comparisons by a paired i-test for the slope data.
E
0)
E
5)
E
U)>
0
0
5)0.0
(1)
—0.3
—0.6
—0.9
—1.2
All pts + Minoxidil + Other drugs
n = 45 orCa blocker N = 26
N = 13
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Discussion
In a previous study we showed that the presence of diastolic
hypertension in patients with pre-existing renal insufficiency
was associated with a more rapid rate of decline in renal
function as determined by the slope of the reciprocal serum
creatinine versus time plot [31. The objective of the present
study was to extend this observation by determining if this
phenomenon was a function of diastolic blood pressure alone or
a function of other pathogenetic processes associated with
hypertension.
One question which we wished to address is whether black
patients with renal insufficiency progress to ESRD more rapidly
than white patients. Hypertensive black patients reach ESRD
more frequently than can be explained by the prevalence of
hypertension [4]. Renal function in black patients with primary
hypertension is associated with decreased renal blood flow [11],
sodium retention [12], and reduced urinary kallikrein excretion
[13] as compared to that in hypertensive white patients. These
factors may predispose the kidneys of hypertensive black
patients to a more rapid progression of disease. The data from
our study indicate that black and white patients had equivalent
rates of progression of renal disease as determined by the
reciprocal creatinine versus time plot as a group (Table I) and
when divided by the presence or absence of diastolic hyperten-
sion (Fig. 1) or type of renal disease (Table 2). Thus, once renal
insufficiency is established and shown to be progressive, black
men do not progress more rapidly than white men, notwith-
standing the significantly higher level of diastolic blood pressure
in the black patients as a group (Table I). These findings were
true for a subgroup of patients with primary hypertension as the
probable cause of their renal disease (Table 2). Therefore, the
increased prevalence of blacks with ESRD probably relates to
other factors such as an increased rate of progressive renal
disease in younger blacks or black females which make up most
of the increased prevalence [4], or to an increased rate of
development of renal insufficiency in blacks with hypertension
as compared to whites [5]. These possibilities were not ad-
dressed in this study.
A second objective of this study was to determine if specific
types of antihypertensive medication have effects on the pro-
gression of renal disease and slow its rate more than expected
with control of hypertension. Numerous studies show that
various treatments preserve renal function in animal models of
progressive renal disease. For example, in rats with reduced
renal mass, inhibitors of angiotensin converting enzyme pre-
serve renal morphology and function better than other antihy-
pertensive medications at the same level of systemic blood
pressure [14, 15]. Thus we hypothesized that specific antihy-
pertensive drugs may have a beneficial effect on the progression
of renal disease even in patients whose diastolic blood pres-
sures were controlled.
To address this hypothesis, we compared rates of change in
reciprocal creatinine versus time plots for groups of patients
treated with a specific antihypertensive regimen (Table 5).
These data indicate that patients who require diuretic treatment
to control blood pressure or extracellular fluid volume had
faster rates of decline in reciprocal creatinine than patients who
do not, and that patients treated with minoxidil had rates of
decline in reciprocal creatinine that were significantly slower
than that of patients who received only diuretics or no treat-
ment for blood pressure control. Our interpretation of these
observations is limited because of nonrandom assignment to
treatment group, small numbers, unknown patient compliance
and the presence of other medications. Therefore, in a second
approach, we examined data from individual patients whose
slope of reciprocal creatinine versus time was determined
before and after addition of a specific antihypertensive medica-
tion. In these patients (Table 6) the diastolic blood pressure was
lowered significantly by the addition of all drugs except pra-
zosin. The effect of these additions on the slope of the recipro-
cal creatinine versus time plot was variable. Addition of beta
blockers or prazosin had no effect. Addition of two drugs or
clonidine tended to slow the rate of decline, but these changes
were not significant because of individual variability and a small
number of observations. However, additions of minoxidil or
calcium channel blockers had a significant, positive effect on
the slope. These drugs were also the most effective in lowering
the diastolic blood pressure, and the effect on the slope of the
reciprocal creatinine versus time plot could be a result of better
control of blood pressure.
To examine this possibility, we looked at data from individual
patients who had a reduction in mean diastolic blood pressure
from greater than 90 mm Hg to a normotensive value. In our
previous study this change was associated with a beneficial
effect on the rate of change of the reciprocal creatinine [3]. In
this study, we found that this effect was dependent upon the
type of medication used to control the blood pressure. Addition
of minoxidil or a calcium channel blocker was associated with a
40% slower rate of change in reciprocal creatinine when dia-
stolic hypertension was controlled. Addition of a beta blocker,
prazosin, clonidine or a combination of two of these drugs had
no significant effect on the rate of change in reciprocal creati-
nine even when diastolic blood pressure was controlled (Fig. 2).
Thus these data suggest that the medication itself and not just
the reduction in systemic blood pressure may have a beneficial
effect on the course of progressive renal disease.
In early literature minoxidil was reported to preserve or
improve renal function acutely in malignant hypertension [16,
171. Only two of the patients in our study had malignant
hypertension with papilledema, so the present data are not due
to that effect of minoxidil. The effectiveness of minoxidil in
"benign" hypertension and renal insufficiency is less clear in
the literature. Mitchell, Graham and Pettinger [17] followed 32
such patients who were treated with minoxidil for an average of
39 months. They reported that many of these patients showed
progression of renal disease even when blood pressure was
adequately controlled [17]. From their data, however, we
calculate the average rate of change of reciprocal creatinine for
these patients to be —0.35 mI/mg month. This value is nearly the
same as reported for our patients (Table 5) and appears to be
significantly lower than the average value for our normotensive
patients who were not treated. The mechanisms involved in
slowing progressive renal disease with minoxidil are unknown.
Our data suggest that the mechanisms are not limited to a
reduction in systemic blood pressure because lowering blood
pressure to a similar extent with other medications did not have
the same beneficial effect (Fig. 2). However, prospective,
randomized studies are needed to confirm this hypothesis.
Calcium channel blockers have been shown to preserve renal
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function during several types of acute [18] and chronic {l9j
renal failure in animals. Chronic verapamil treatment of rats
with the five sixths nephrectomy model of renal insufficiency
preserved renal function without significantly lowering mean
arterial blood pressure [19]. This suggests that mechanisms
other than blood pressure control underlie this protective effect.
These mechanisms may include blocking tissue calcium accu-
mulation during injury [19, 20] or blocking the hypermetabolism
that appears to be associated with a reduction in renal mass
[211. Similar mechanisms may occur in patients. Renal tissue
from patients with renal disease had a higher calcium content
than renal tissue from autopsied controls [221. These authors
suggest that tissue calcium content was elevated early in the
course of renal disease and aggravated by elevations in plasma
phosphate. Eliahou et at [23] recently reported on a randomized
trial in patients with progressive renal disease comparing treat-
ment with a calcium channel blocker to treatment with other
antihypertensive medications (beta blockers, prazosin or hy-
dralazine). The 17 patients treated with nisoldipine, a calcium
channel blocker, showed a significant improvement in the slope
of the reciprocal creatinine (from —0.75 mi/mg month to —0.49)
whereas the 17 patients in the control group had no change
(—0.46 mI/mg month to —0.52) during the 17 month follow-up
period. There was no significant change in diastolic blood
pressure during the treatment period. These data and the data
from our study support the hypothesis that treatment with
calcium channel blockers may preserve renal function in the
setting of renal insufficiency by mechanisms in addition to a
reduction in systemic blood pressure.
The results of our study may be limited by the patient
population on which it is based. The patients were derived from
a VA Nephroiogy Clinic over a 9.5 year period. The Durham
VA Medical Center provides care for all eligible veterans in a
region that includes most of North Carolina, a population of
older males. Therefore, the conclusions drawn from this study
may not be applicable to young patients or women. The average
rate of decline in the slope of reciprocal creatinine versus time
in this population, however, was similar to that reported for
other populations. For example, the mode for the slope of
reciprocal creatinine plots was —0.6 mI/mg month for predial-
ysis patients followed by clinics at Johns Hopkins and Montreal
General Hospitals [24]. Diabetic patients with renal disease
followed at the Joslin Clinic had an average reciprocal creati-
nine slope of —0.2 mi/mg month when diastolic blood pressure
was normal and —0.7 mi/mg month when it was not [251. Walker
et at [26] reported that patients followed at Johns Hopkins
Hospital with diabetic nephropathy and hypertension had an
average reciprocal creatinine slope of —0.8 mI/mg month if they
were insulin-dependent and —1.0 mI/mg month if they were
non-insulin dependent. Thus, these preliminary reports from
other medical centers indicate that their patient populations
have comparable rates of change in reciprocal creatinine to
those observed in our population.
In summary, this retrospective study of a iarge population of
veterans with progressive renal insufficiency indicates that
there are no differences between black and white patients in the
rate of progression as determined by the slope of the reciprocal
creatinine versus time or in the response of renal disease to the
presence of hypertension. Additionally, in this population, the
use of specific antihypertensive medications such as minoxidil
and calcium channel blockers was associated with a significant
slowing of the progression of renal disease. This effect was not
seen with other antihypertensive medications and appeared to
be additive to the beneficial effect of lowering the diastolic
blood pressure. The mechanisms involved in this protective
effect are unknown. These data, however, indicate that it may
be possible to slow the rate of progressive renal disease with
medications. Prospective studies are needed to directly address
this possibility and to determine pathogenetic mechanisms.
Acknowledgments
These data were presented in part at the Annual Meeting of the
American Society of Nephrology in San Antonio, TX, December, 1988
and an abstract was published in Kidney mt 35:190, 1989. Support for
these studies was provided by the Research Service of the Veterans
Administration. Dr. Brazy is an Established Investigator of the Amer-
ican Heart Association.
Reprint requests should be mailed to Dr. Peter C. Brazy, H4/510
Clinical Sciences Center, University of Wisconsin, 600 Highland Ave.,
Madison, Wisconsin 53792, USA.
References
1. LINDEMAN RD, TOBIN JD, SHOCK NW: Association between blood
pressure and the rate of decline in renal function with age. Kidney
mt 26:861—868, 1984
2. MOGENSEN CE: Long-term anti-hypertensive treatment inhibiting
progression of diabetic nephropathy. Brit Med J 285:685—688, 1982
3. Bzv PC, STEAD WW, FITzwILLIAM JF: Progression of renal
insufficiency: Role of blood pressure. Kidney mt 35:670—674, 1989
4. MCCLELLAN W, TUTTLE E, IssA A: Racial differences in the
incidence of hypertensive ESRD are not entirely explained by
differences in prevalence of hypertension. Am J Kid Dis 12:
285—290, 1988
5. ROSTAND SG, BROWN G, KIRK KA, RUTSKY EA, DUSTAN HP:
Renal insufficiency in treated essential hypertension, N Engi J Med
320:684—688, 1989
6. DUSTAN HP, CURTIS JJ, LUKE RG, ROSTAND SG: Systemic
hypertension and the kidney in black patients. Am J Cardiol 60
(Supp I):731—771, 1987
7. STEAD WW, GARRETT LE JR, HAMMOND WE: Practicing nephrol-
ogy with a computerized medical record. Kidney mt 24:446—454,
1983
8. MITCH WE, WALSER M, BUFFINGTON GA, LEMANN J JR: A simple
method for estimating progression of chronic renal failure. Lancet
2:1326—1328, 1976
9. RUTHERFORD WE, BLONDIN J, MILLER JP, GREENWALT AS,
VAVRA JD: Chronic progressive renal disease: rate of change of
serum creatinine concentration. Kidney mt 11:62—70, 1977
10. WALSER M, DREW HH, LAFRANCE ND: Creatinine measurements
often yield false estimates of progression in chronic renal failure.
Kidney mt 34:412—418, 1988
11. LEVY SB, TALNER LB, COEL MN, HOLLE R, STONE RA: Renal
vasculature in essential hypertension: Racial differences. Ann In-
tern Med 88: 12—16, 1978
12. SOwERS JR, ZEMEL MB, ZEMEL P, BECK FW, WALSH MF,
ZAwADA ET: Salt sensitivity in blacks. Salt intake and natriuretic
substances. Hypertension 12:485—490, 1988
13. LEVY SB, LILLEY JJ, FRIGON RP, STONE RA: Urinary kallikrein
and plasma renin activity as determinants of renal blood flow. The
influence of race and dietary sodium intake. J Cliii Invest 60:
129—138, 1977
14. ANDERSON 5, MEYERTW, RENNKE HG, BRENNER BM: Control of
glomerular hypertension limits glomerular injury in rats with re-
duced renal mass. J Clin Invest 76:612—619, 1985
IS. ANDERSON S. RENNKE HG, BRENNER BM: Therapeutic advantage
of converting enzyme inhibitors in arresting progressive renal
disease associated with systemic hypertension in the rat. J C/in
Invest 77:1993—2000, 1986
Brazy and Fitzwilliam: Progressive renal disease 1119
16. MROCZEK WJ, Dvinov M, GAVRILOVICH L, FINNERTY FA JR:
The value of aggressive therapy in the hypertensive patient with
azotemia. Circulation 40:893—904, 1969
17. MITCHELL HC, GRAHAM RM, PETTINGER WA: Renal function
during longer-term treatment of hypertension with minoxidil: Com-
parison of benign and malignant hypertension. Ann Intern Med
93:676—681, 1980
18. SCHRIER RW, ARNOLD PE, VAN PUTTEN VJ, BURKE Ti: Cellular
calcium in ischemic acute renal failure: role of calcium entry
blockers. Kidney mt 32:313—321, 1987
19. HARRIS DCH, HAMMOND WS, BURKE TJ, SCHRIER RW: Vera-
pamil protects against progression of experimental chronic renal
failure. Kidney In! 31:41—46, 1987
20. GOLIGORSKY MS, CHAIM0vITs C, RAPOPORT J, GOLDSTEIN J, KOL
R: Calcium metabolism in uremic nephrocalcinosis: Preventive
effect of verapamil. Kidney mt 27:774—779, 1985
21. HARRIS DCH, CHAN L, SCHRIER RW: Remnant kidney hyperme-
tabolism and progression of chronic renal failure. Am J Physiol 254
(Renal Fluid Electro Physiol 23):F267—F276, 1988
22. GIMENEZ LF, SOLEZ K, WALKER WG: Relation between calcium
content and renal impairment in 246 human renal biopsies. Kidney
mt 31:93—99, 1987
23. ELIAHOU HE, COHEN D, HELLBERG B, BEN-DAVID A, HERZOG D,
SHECHTER P, KAPULER 5, KOGAN N: Effect of the calcium channel
blocker nisoldipine on the progression of chronic renal failure in
man. Am J Nephrol 8:285—290, 1988
24. WALSER M, STALLINGS J, HUTCHINSON T: Characterization of
progression of chronic renal failure in pre-dialysis patients. (ab-
stract) Clin Res 32:565A, 1984
25. LAFFEL LMB, KROLEWSKI AS, RAND LI, WARRAN JH, CHRIS-
TLIEB AR, D'ELIA JA: The impact of blood pressure on renal
function in insulin-dependent diabetes. (abstract) Kidney In! 31:
207, 1987
26. WALKER WG, HERMANN J, YIN DP, YOUNG L, ROUKE L: Com-
parison of rates of change in nephropathy in insulin dependent and
non-insulin dependent diabetes mellitus. (abstract) Kidney mt
31:222, 1987
